Simon Mitchell

Systems biology @bsmsMedSchool | UKRI Future Leaders Fellow | co-director @sussex_cancer | Speciality Chief Editor: Systems Immunology @FrontImmunol

[Simon Mitchell @SiFTW]

https://t.co/HFgoZs4XYZ

[Simon Mitchell @SiFTW]

We’re excited to announce that we’re looking for a postdoctoral research to join our team!
This is an opportunity to lead an exciting project aiming to push the boundaries of personalised medicine through integrating data, simulation and lab experiments.
https://t.co/lfFDF2CY2H

[Sussex Cancer Research Centre @Sussex_Cancer]

We're excited to annoucen that @SxCancerFund SCRC research awards are open for applications, with funding up to £10k or £30k. Priority areas include data science, population datasets, prevention, early diagnosis, and mental health.
https://t.co/6oNrZOxekR

[Simon Mitchell @SiFTW]

@drol007 @BSMSMedSchool @Sussex_Cancer Very important!

[BSMS @BSMSMedSchool]

✨ How is BSMS lighting the way in cancer research?
Dr Simon Mitchell (@SiFTW) & Prof Melanie Flint share the mission at the Sussex Cancer Research Centre: pioneering interdisciplinary research that will improve cancer treatments & outcomes. @Sussex_Cancer
https://t.co/39TK4e1LZ6

[Simon Mitchell @SiFTW]

@alex_tonks @BSMSMedSchool @SussexUni @uniofbrighton Thank you so much Alex

[Simon Mitchell @SiFTW]

Excited to have been promoted to Professor in Cancer Systems Biology at @BSMSMedSchool, @SussexUni, @uniofbrighton

[Simon Mitchell @SiFTW]

@MariaTeresaEs @Sussex_BCR Thank you so much!

[Simon Mitchell @SiFTW]

I especially owe this promotion to the incredible and inspiring scientists that I’m fortunate enough to call my team, collaborators, and co-directors of @Sussex_Cancer
I’m most excited to use my position to repay some of the incredible support I’ve had by supporting others.
🍻

[Simon Mitchell @SiFTW]

Reflecting triggers imposter syndrome tbh. But I owe it to a series of advisors/supervisors/mentors who believed in me and my approaches.
Particularly, Pedro Mendes, @ahoffmann2716, and @ChrisPepper64, who supported me in so many ways from PhD, to postdoc, and PI respectively.

[Rhys Morgan @RhysMorganLab]

Very grateful to have been awarded our 1st @bloodcancer_uk @BloodCancer_Res research grant over the summer for our work targeting aberrant Wnt/β-catenin signalling in acute myeloid leukaemia (AML).

New project begins Oct 1st developing new ways to target oncogenic β-catenin 👊

[Simon Mitchell @SiFTW]

I’ll forever be grateful to @LeukUK and their supporters for being the first to support our work using simulations to tailor treatments in blood cancer.
Our lab @BSMSMedSchool and @Sussex_Cancer exists because of you.
It was fun to share some of what I’ve learned with ECRs today.

[Leukaemia UK @LeukUK]

“There’s no way I’d be sitting in front of you now if I didn’t receive the John Goldman Fellowship.”

Some established researchers share their experiences and advice for those starting out in the field. 🔬🧡

[Leukaemia UK @LeukUK]

“There’s no way I’d be sitting in front of you now if I didn’t receive the John Goldman Fellowship.”

Some established researchers share their experiences and advice for those starting out in the field. 🔬🧡

[Sussex Cancer Research Centre @Sussex_Cancer]

Have you or a loved one experienced cancer?

We’re looking for volunteers with lived experience of cancer to join our Experts by Experience panel.
Your voice can help shape the future of cancer research in Sussex.

Apply here: https://t.co/CWvSYB1kV1
Apply by 30/09/2025

[Leukaemia UK @LeukUK]

Congrats to our John Goldman Fellow, @SiFTW and team! Their research shows how lymphoma cells evade treatment by switching between “survival” pathways. The team have discovered how to predict and overcome this resistance, which could lead to more tailored treatments. 👏

[Simon Mitchell @SiFTW]

@LeukUK Thank you @LeukUK and all your supports for making this research possible.
Let’s keep working towards personalising treatments for blood cancers so everyone can have better outcomes.

[Simon Mitchell @SiFTW]

Summary
- Targeting BCL2/MCL1/BCLXL requires unstanding the TME.
- Systems biology can identify inhibitors that make BH3-mimetics great again.
We're now working on clinical translation, making simulations easy to interpret, and in vivo testing of personalised medicine.
end/🧵

[Simon Mitchell @SiFTW]

New paper led by Aimilia Vareli out now.
https://t.co/3XZNZkos54
The lymphoma microenvironment stops BH3-mimetics from working.
In vitro/vivo/silico, we find that inhibition of NFκB makes BH3-mimetics great again.
1/🧵
@Sussex_BCR @Sussex_Cancer @LeukUK @BSMSMedSchool #UKRIFLF

[Simon Mitchell @SiFTW]

Finally, we find that despite all this complexity there is one strategy that always works to overcome the TME.
Inhibition of the key regulator of non-canonical NF-kB (NIK) totally neutralises the drug resistance caused by the TME in DLBCL🎉
5/🧵